PFE

Pfizer's post-COVID comeback is still only in the early stages.

Pfizer's dividend yield sits near 6%, but the company paid out more in dividends last year than it generated in free cash flow. Before income investors panic or pile in, the real story behind that coverage gap deserves a close look.

Pfizer has surpassed the broader S&P 500 Index over the past year, and analysts are cautious about the stock’s prospects.

Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO met the primary endpoint in relapsed or refractory multiple myeloma, while the FDA expanded approval of TALZENNA plus XTANDI for men with metastatic hormone sensitive prostate cancer with…

ROI strategies: invest in next-gen ADCs and TKIs, expand biomarker-led and combination therapies, add biosimilars, scale biologics capacity, and pursue acquisitions.Dublin, Oct.

SAN FRANCISCO, October 29, 2026--Edison Scientific announces agreement with Pfizer to accelerate research and development

Get a deeper insight into the potential performance of Pfizer (PFE) for the quarter ended September 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

Pfizer (NYSE:PFE) reports third-quarter results before the open on Tuesday, Nov. 3. Shares have gained 25% year to date. This report tests whether non-COVID growth and obesity progress can keep outpacing a shrinking pandemic franchise.

Pfizer (PFE) closed at $29.45 in the latest trading session, marking a -1.17% move from the prior day.

Pfizer heads into Q3 earnings with strong drug sales and an attractive valuation, but declining COVID revenues and looming patent expirations pose challenges.

For questions about this article or underlying research, email [email protected].

Pfizer (NYSE:PFE) reported positive Phase 3 MagnetisMM-32 results for ELREXFIO in relapsed or refractory multiple myeloma.